DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus

Area of Science:

• Endocrinology
• Hepatology
• Pharmacology

Background:

• Incretin receptors are present in various tissues, including the liver, suggesting potential pleiotropic effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors.
• The impact of DPP-4 inhibitors on liver function in patients with type 2 diabetes remains an area of investigation.

Purpose of the Study:

• To investigate the effect of DPP-4 inhibitors on liver function in patients diagnosed with type 2 diabetes.
• To determine if DPP-4 inhibitors can ameliorate existing liver dysfunction in this patient population.

Main Methods:

• A retrospective review was conducted on 459 patients with type 2 diabetes prescribed DPP-4 inhibitors.
• After exclusions for conditions affecting liver function, 224 patients were included in the final analysis.

Main Results:

• Liver injury, defined by elevated AST or ALT levels (>40 U/L), was observed in 19.6% of patients.
• Following 6 months of DPP-4 inhibitor treatment, significant reductions in AST (mean change -6.2 U/L) and ALT (mean change -11.9 U/L) were noted.
• Percent changes in AST and ALT showed significant negative correlations with baseline AST and ALT levels.

Conclusions:

• DPP-4 inhibitors demonstrated a positive effect on improving liver dysfunction in patients with type 2 diabetes.
• The findings suggest a beneficial role for DPP-4 inhibitors in managing liver health in this demographic.